Loading...
•
Jun 30, 2021
Regulus Therapeutics Q2 2021 Earnings Report
Regulus Therapeutics reported financial results for Q2 2021 and provided a corporate update.
Key Takeaways
Regulus Therapeutics reported a net loss of $6.0 million, or $0.08 per share, for the second quarter ended June 30, 2021. The company's cash and cash equivalents totaled $41.4 million as of June 30, 2021, and it expects its cash resources to fund planned activities into Q4 2022.
Completed preparations and requested an FDA meeting to obtain feedback on addressing remaining hold requirements.
Completed enrollment in the second cohort of the Phase 1b trial; topline data is expected in the fourth quarter.
Extended the expected cash runway into Q4 2022 with $15.4 million raised through its At-The-Market (ATM) facility.
Demonstrated clinical proof of mechanism with results from the first cohort of data in the Phase 1b clinical trial of RGLS4326 for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Regulus Therapeutics
Regulus Therapeutics
Forward Guidance
Regulus Therapeutics expects its existing cash will provide cash resources to fund planned activities into Q4 2022.